Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort

Histological fibrosis staging by liver biopsy is invasive, impractical at scale, and inaccessible in community settings, yet drug developers and clinicians lacked a validated, biopsy-free prognostic system that could stratify NAFLD patients by mortality and clinical event risk using widely available data.

The TARGET-NASH longitudinal real-world cohort was used to validate a pragmatic, FIB-4- and clinical criteria-based risk classification system against hard outcomes—mortality, liver events, and MACE—across a large, diverse US population spanning academic and community sites.

Providing a validated three-tiered prognostic classification applicable universally, without biopsy, equips drug developers with a scalable patient stratification tool for trial enrollment and supports regulatory endpoints grounded in real-world clinical outcomes.

Non-invasive risk stratification of MASLD patients for trial enrollment, Outcome-based validation of FIB-4 and clinical algorithms, Real-world prognostic benchmarking for drug development endpoints